Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Marianna PucciniChristian RauchKai JakobsJulian FriebelAdel HassaneinUlf LandmesserUrsula RauchPublished in: Cardiovascular drugs and therapy (2022)
Despite the use of DAPT, a higher platelet reactivity was found in overweight and obese patients with CCS. If these patients will benefit from treatment with more potent platelet inhibitors, it needs to be evaluated in future clinical trials.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- clinical trial
- end stage renal disease
- weight loss
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- metabolic syndrome
- coronary artery disease
- physical activity
- low dose
- type diabetes
- prognostic factors
- current status
- cardiovascular disease
- randomized controlled trial
- body mass index
- weight gain
- atrial fibrillation
- bariatric surgery
- anti inflammatory
- study protocol